| Literature DB >> 32215037 |
Fang Lai1,2,3, Yang Ren1, Chengzhi Lai1, Rui Chen2, Xuelian Yin4, Caixia Tan1, Jiansen Li1, Chunmei Yang5, Guorong Liang2, Jun Li2, Ruifeng Zeng2,6.
Abstract
BACKGROUND: Sepsis is a global major health problem with high mortality rates. More effective therapy is needed for treating sepsis. Acupuncture has been used for various diseases, including severe infection, in China for more than 2,000 years. Previous studies reported that acupuncture at Zusanli (ST36) might be effective in treating sepsis, but the efficacy and the quality of evidence remain unclear since there is no systematic review on acupuncture at ST36 for sepsis.Entities:
Year: 2020 PMID: 32215037 PMCID: PMC7081026 DOI: 10.1155/2020/3620741
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Flow diagram showing study selection process. CENTRAL, the Cochrane Central Register of Controlled Trials in The Cochrane Library; CNKI, Chinese National Knowledge Infrastructure; CBM, Chinese Biomedical Literature Database; CHM, Chinese herbal medicine.
Model details of included trials.
| Study (years) | Model (method) |
|---|---|
| Cao et al., [ | 5 mg/kg LPS, i.v. |
| Dong et al., [ | 0.5 mL (5 mg/kg) LPS, i.v. |
| Gao et al., [ | 5 mg/kg LPS, i.v. |
| Gao et al., [ | 5 mg/kg LPS, i.v. |
| Gong et al., [ | 5 mg/kg LPS, i.v. |
| Guo et al., [ | 5 mg/kg LPS, i.v. |
| Han et al., [ | 5 mg/kg LPS, i.v. |
| Shi et al., [ | 5 mg/kg LPS, i.v. |
| Song et al., [ | 5 mg/kg LPS, i.v. |
| Wang et al., [ | 5 mg/kg LPS, i.v. |
| Yu et al., [ | 0.5 mL (5 mg/kg) LPS, i.v. |
| Yu et al., [ | 0.5 mL (5 mg/kg) LPS, i.v. |
| Yu et al., [ | 0.5 mL (5 mg/kg) LPS, i.v. |
| Zhang et al., [ | 0.5 mL (5 mg/kg) LPS, i.v. |
| Zhang et al., [ | 0.5 mL (5 mg/kg) LPS, i.v. |
| Zhang et al., [ | 5 mg/kg LPS, i.v. |
| Zhang et al., [ | 5 mg/kg LPS, i.v. |
| Zhang et al., [ | 2mL (5 mg/kg) LPS, i.v. |
| Zhang et al., [ | 2mL (5 mg/kg) LPS, i.v. |
| Zhang et al., [ | 5 mg/kg LPS, i.v. |
| Cao et al., [ | CLP, no details |
| Chen et al., [ | CLP, ligated 50% of the cecum with no. 0 silk, perforated once with 18-gauge needles (two pores) |
| Chen et al., [ | CLP, ligated 50% of the cecum with no. 0 silk, perforated once with 18-gauge needles (two pores) |
| Gu et al., [ | 5 mg/kg LPS i.v. |
| Guo et al., [ | CLP, ligated the cecum with no. 30 silk, perforated once with 22-gauge needles (two pores) |
| Hu et al., [ | 5 mg/kg LPS i.v. |
| Hu et al., [ | CLP, ligature the root of the cecum, perforated 3 times with a no. 16 needle |
| Hu et al., [ | CLP, no details |
| Hu et al., [ | CLP, ligature the root of the cecum, perforated 3 times with a no. 16 needle |
| Hu et al., [ | CLP, ligature the root of the cecum, perforated 3 times with a no. 16 needle |
| Huang et al., [ | 20 mg/kg LPS, intraperitoneally |
| Huang et al., [ | 20 mg/kg LPS, intraperitoneally |
| Yue et al., [ | 20% of the TBSA III degree burns on the back of the rat by boiling water (99°C–100°C, 12 s), following by 5 mg/kg MDP i.v. |
| Lei et al., [ | CLP, ligated the cecum with no. 30 silk, perforated once with 22-gauge needles (two pores) |
| Lei et al., [ | CLP, ligated the cecum with no. 30 silk, perforated once with 22-gauge needles (two pores) |
| Lei et al., [ | CLP, ligated 50% of the cecum with no. 0 silk, perforated with 18-gauge needles (two pores) |
| Shi et al., [ | CLP, ligature the root of the cecum, perforated 3 times with a no. 16 needle |
| Song et al., [ | 5 mg/kg LPS, i.v. |
| Song et al., [ | 20% of the TBSA III degree burns on the back of the rat by boiling water (99°C–100°C, 12 s), following by 5 mg/kg MDP i.v. |
| Villegas-Bastida et al., [ | CLP, ligated just proximal to the ileocecal valve, perforated twice with 21-gauge needles at 5 mm distal to the point of ligation |
| Wang et al., [ | 30 mg/kg LPS, i.v. |
| Wang et al., [ | CLP, ligated the root of the cecum, perforated 3 times with a no. 16 needle |
| Wang et al., [ | CLP, ligated 1/3 of the cecum from the ileocecal valve with no. 0–4 silk, perforated with 18-gauge needles |
| Wu et al., [ | CLP, ligated the root of the cecum, perforated 4 times with a no. 16 needle |
| Wu et al., [ | CLP, ligated the root of the cecum, perforated 4 times with a no. 16 needle |
| Wu et al., [ | CLP, ligated the root of the cecum, perforated 4 times with a size 16 needle |
| Xu et al., [ | CLP, no details |
| Yang et al., [ | CLP, ligated the root of the cecum, perforated 2 pores with a no. 12 needle |
| Zhang et al., [ | CLP, ligated the root of the cecum, perforated 3 times with a size 16 needle |
| Zhang et al., [ | 20% of the TBSA III degree burns on the back of the rat by boiling water (99°C–100°C, 12 s), following 5 mg/kg MDP i.v. |
| Zhang et al., [ | CLP, ligated the root of the cecum, perforated 3 times with no. 16 needle |
| Zhang et al., [ | CLP, ligated the lower section of the cecum (25% from the blind side of its total length) using 4–0 silk threads, perforated once with a 19-gauge needle |
| Zhu et al., [ | CLP, ligated the base of the cecum, below the ileocecal valve, with a 2.0-silk, perforated 2 times with no.18 needle |
| Torres-Rosas et al., [ | (1) 6 mg/kg LPS, intraperitoneally |
Note. LPS: lipopolysaccharide; i.v.: intravenously; CLP: cecal ligation and puncture; TBSA: total body surface area; MDP : muramyl dipeptide.
Study quality and risk of bias.
| Study (years) | (1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) | (9) | (10) | (11) | (12) | (13) | (14) | (15) | (16) | (17) | Total | Scores | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| + | ± | ? | – | |||||||||||||||||||
| Cao et al., [ | + | ± | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 2 | 0 | 10 | 6 |
| Dong et al., [ | + | ± | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 2 | 0 | 10 | 6 |
| Gao et al., [ | + | + | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 6 | 1 | 0 | 10 | 6.5 |
| Gao et al., [ | –△ | + | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 1 | 0 | 11 | 5.5 |
| Gong et al., [ | + | ± | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 2 | 0 | 10 | 6 |
| Guo et al., [ | + | – | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 1 | 0 | 11 | 5.5 |
| Han et al., [ | + | ± | + | ±◆ | – | – | – | – | + | – | – | – | + | + | + | – | – | 6 | 2 | 0 | 9 | 7 |
| Shi et al., [ | + | ± | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 2 | 0 | 10 | 6 |
| Song et al., [ | + | ± | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 2 | 0 | 10 | 6 |
| Wang et al., [ | –△ | ± | + | ±◆ | – | – | – | – | – | – | – | – | + | + | ± | – | – | 3 | 3 | 0 | 11 | 4.5 |
| Yu et al., [ | + | ± | + | – | – | – | – | ± | – | + | – | – | + | + | – | – | – | 5 | 2 | 0 | 10 | 6 |
| Yu et al., [ | + | ± | + | – | – | – | – | ± | – | + | – | + | + | ± | + | – | – | 6 | 3 | 0 | 8 | 7.5 |
| Yu et al., [ | + | ± | + | – | – | – | – | ± | – | + | – | – | + | ± | + | – | – | 5 | 3 | 0 | 9 | 6.5 |
| Zhang et al., [ | –△ | + | + | ±◆ | – | – | – | ± | – | – | – | – | + | + | + | – | – | 5 | 2 | 0 | 10 | 6 |
| Zhang et al., [ | –△ | + | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 1 | 0 | 11 | 5.5 |
| Zhang et al., [ | + | ± | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 2 | 0 | 10 | 6 |
| Zhang et al., [ | + | ± | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 2 | 0 | 10 | 6 |
| Zhang et al., [ | + | – | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 1 | 0 | 11 | 5.5 |
| Zhang et al., [ | + | – | + | – | – | – | – | – | – | + | – | – | + | – | + | – | – | 5 | 0 | 0 | 12 | 5 |
| Zhang et al., [ | + | – | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 1 | 0 | 11 | 5.5 |
| Cao et al., [ | + | – | + | – | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 0 | 0 | 12 | 5 |
| Chen et al., [ | + | + | + | – | – | – | – | ± | – | + | – | + | + | ± | + | – | – | 7 | 2 | 0 | 8 | 8 |
| Chen et al., [ | + | – | + | – | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 0 | 0 | 12 | 5 |
| Gu et al., [ | + | ± | + | ±◆ | – | – | – | + | + | + | – | + | + | ± | + | – | – | 8 | 3 | 0 | 6 | 9.5 |
| Guo et al., [ | + | – | + | ±◇ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 1 | 0 | 11 | 5.5 |
| Hu et al., [ | + | – | + | – | – | – | – | – | – | – | – | – | + | ± | – | – | – | 3 | 1 | 0 | 13 | 3.5 |
| Hu et al., [ | + | – | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 1 | 0 | 11 | 5.5 |
| Hu et al., [ | + | – | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 1 | 0 | 11 | 5.5 |
| Hu et al., [ | + | – | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 1 | 0 | 11 | 5.5 |
| Hu et al., [ | + | – | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 1 | 0 | 11 | 5.5 |
| Huang et al., [ | + | ± | + | – | – | – | – | – | – | + | – | – | + | ± | – | – | – | 4 | 2 | 0 | 11 | 5 |
| Huang et al., [ | + | – | + | ±◆ | + | – | – | + | – | + | – | – | + | ± | – | – | – | 6 | 2 | 0 | 9 | 7 |
| Yue et al., [ | + | – | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 1 | 0 | 11 | 5.5 |
| Lei et al., [ | + | – | + | ±◇ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 1 | 0 | 11 | 5.5 |
| Lei et al., [ | + | – | + | ±◇ | – | – | – | – | – | – | – | – | + | + | – | – | – | 4 | 1 | 0 | 12 | 4.5 |
| Lei et al., [ | –△ | – | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 4 | 1 | 0 | 12 | 4.5 |
| Shi et al., [ | + | ± | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 2 | 0 | 10 | 6 |
| Song et al., [ | + | ± | + | – | – | – | – | – | – | – | – | – | + | ± | – | – | – | 3 | 2 | 0 | 12 | 4 |
| Song et al., [ | + | – | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 1 | 0 | 11 | 5.5 |
| Villegas-Bastida et al., [ | + | ± | – | – | – | – | – | – | – | + | – | + | + | ± | + | – | – | 5 | 2 | 0 | 10 | 6 |
| Wang et al., [ | –△ | ± | – | – | – | – | – | – | – | – | – | – | – | ± | + | – | – | 1 | 2 | 0 | 14 | 2 |
| Wang et al., [ | + | + | + | ±◆ | – | – | – | – | – | ? | – | – | + | + | + | – | – | 6 | 1 | 1 | 9 | 7 |
| Wang et al., [ | + | ± | + | ±◆ | – | – | – | – | – | – | – | – | + | ± | – | – | – | 3 | 3 | 0 | 11 | 4.5 |
| Wu et al., [ | –△ | + | + | – | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 0 | 0 | 12 | 5 |
| Wu et al., [ | + | – | + | ±◆ | – | – | – | – | – | – | – | – | + | + | – | – | – | 4 | 1 | 0 | 12 | 4.5 |
| Wu et al., [ | + | + | + | ±◆ | – | – | – | – | – | + | – | – | + | ± | + | – | – | 6 | 2 | 0 | 9 | 7 |
| Xu et al., [ | + | – | + | – | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 0 | 0 | 12 | 5 |
| Yang et al., [ | + | – | + | ±◆ | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 1 | 0 | 11 | 5.5 |
| Zhang et al., [ | + | ± | + | ±◆ | – | – | – | – | – | – | – | – | + | + | – | – | – | 4 | 2 | 0 | 11 | 5 |
| Zhang et al., [ | + | – | + | – | – | – | – | – | – | – | – | – | + | + | + | – | – | 5 | 0 | 0 | 12 | 5 |
| Zhang et al., [ | + | ± | – | – | – | – | – | – | – | + | – | – | + | + | + | – | – | 5 | 1 | 0 | 11 | 5.5 |
| Zhang et al., [ | + | ± | + | ±◆ | – | – | – | – | – | + | – | – | + | – | + | – | – | 5 | 2 | 0 | 10 | 6 |
| Zhu et al., [ | + | ± | – | – | – | – | – | – | – | + | – | + | + | ± | + | – | – | 5 | 2 | 0 | 10 | 6 |
| Torres-Rosas et al., [ | + | ± | + | – | – | – | – | + | – | + | – | + | + | – | + | – | – | 7 | 1 | 0 | 9 | 7.5 |
Note. (1) Peer-reviewed publication; (2) control of temperature, humidity, and light; (3) randomized allocation; (4) reporting details of randomized allocation method; (5) allocation concealment; (6) blinded model induction; (7) blinded intervention administration; (8) blinded outcome assessment; (9) sample size calculation or explanation; (10) animal welfare regulations compliance statement; (11) being free of selective reporting; (12) potential conflict of interests statement; (13) reporting statistical method; (14) reporting numerical data in Results; (15) reporting actual numbers of animal samples of different groups in Results; (16) completeness of follow-up; and (17) intention-to-treat analysis. +: yes, scores 1 point; –: no, scores 0 points; ±: partially yes, scores 0.5 points; ?: unclear, scores 0 points; △unpublished Ph.D.'s or Master's thesis; ◇randomized allocation according to blocked randomization; details are unavailable; ◆randomized allocation according to random number table; details are unavailable.
Characteristics of the included studies.
| Study (years) | Outcome index | Intergroup differences▽ |
|---|---|---|
| Cao et al., [ | (1) Renal injury scores(2) BUN(3) Cr(4) MDA (renal)(5) SOD (renal)(6) PKC | All |
| Dong et al., [ | (1) Lung injury scores(2) AI (alveolar epithelial cell)(3) HO-1(lung)(4) HO-1 mRNA (lung) | All |
| Gao et al., [ | (1) Oxygenation Indexes(2) Lung injury scores(3) W/D (lung)(4) MDA (lung)(5) SOD (lung)(6) p38MAPK (lung)(7) p38MAPK phosphorylation (lung)(8) Nrf2 nucleoprotein relative expressions (lung)(9) Nrf2 total protein relative expressions (lung)(10) Nrf2 mRNA (lung) | All |
| Gao et al., [ | (1) Lung injury scores(2) W/D (lung)(3) SOD (lung)(4) MDA (lung)(5) p38MAPK (lung)(6) Nrf2 mRNA (lung)(7) Nrf2 total protein relative expressions (lung) | All |
| Gong et al., [ | (1) Lung injury scores(2) W/D (lung)(3) MDA (lung)(4) SOD (lung)(5) HO-1 mRNA (lung)(6) Nrf2 total protein relative expressions (lung) | (1) |
| Guo et al., [ | (1) Renal injury scores(2) W/D (renal)(3) | All |
| Han et al., [ | (1) Lung injury scores(2) SOD (lung)(3) MDA (lung)(4) TNF- | All |
| Shi et al., [ | (1) Lung injury scores(2) W/D (lung)(3) SOD (lung)(4) MDA (lung)(5) Nrf2 mRNA (lung)(6) Nrf2 nucleoprotein relative expressions (lung)(7) Nrf2 total protein relative expressions (lung) | All |
| Song et al., [ | (1) Lung injury scores(2) W/D (lung)(3) MDA (lung)(4) SOD (lung)(5) Nrf2 nucleoprotein relative expressions (lung)(6) Nrf2 total protein relative expressions (lung)(7) PKC | All |
| Wang et al., [ | (1) Renal injury scores(2) AI (renal)(3) BUN(4) Cr(5) TNF- | All |
| Yu et al., [ | (1) SOD (lung)(2) MDA (lung)(3) EB contents (lung)(4) W/D (lung)(5) CO(6) Lung injure score(7) HO-1 mRNA(8) HO-1 | All |
| Yu et al., [ | (1) The death rate (the animals were supplemented)(2) MAP after EA for 30 min(3) MAP after LPS for 30 min(4) MAP after LPS for 60 min(5) MAP after LPS for 90 min(6) MAP after LPS for 120 min(7) Oxygenation indexes(8) W/D (lung)(9) MDA (lung)(10) SOD (lung)(11) CAT(12) GPx(13) TNF- | (1) NA△, NA◇(2) |
| Yu et al., [ | (1) SOD (renal)(2) MDA (renal)(3) IL-10(4) TNF- | All |
| Zhang et al., [ | (1) Lung injury scores(2) W/D (lung)(3) Oxygenation indexes(4) MDA (lung)(5) SOD (lung)(6) HO-1 (lung)(7) NF-κBp65 (lung)(8) HO-1 mRNA (lung)(9) TNF- | (1) |
| Zhang, [ | (1) Lung injury scores(2) W/D (lung)(3) Oxygenation indexes(4) MDA (lung)(5) SOD (lung)(6) TNF- | (1) |
| Zhang et al., [ | (1) Lung injury scores(2) W/D (lung)(3) MDA (lung)(4) SOD (lung)(5) HO-1 mRNA (lung)(6) HO-1 (lung)(7) NF-κBp65total protein relative expressions (lung)(8) NF-κBp65 nucleoprotein relative expressions (lung) | All |
| Zhang et al., [ | (1) Lung injury scores(2) TNF- | All |
| Zhang et al., [ | (1) Cardiac injury scores(2) CK(3) LDH(4) TNF- | All |
| Zhang et al., [ | (1) Lung injury score(2) W/D (lung)(3) SOD (lung)(4) MDA (lung)(5) TNF- | All |
| Zhang et al., [ | (1) ATP (lung)(2) ROS (lung)(3) Mfn1 mRNA (lung)(4) Mfn2 mRNA (lung)(5) OPA1 mRNA (lung)(6) DRP1 mRNA (lung)(7) Mfn1 (lung)(8) Mfn2 (lung)(9) OPA1 (lung)(10) DRP1 (lung) | All |
| Cao et al., [ | (1) HR(2) LVEDP(3) LVSP(4) dp/dtmax(5) CO(6) TNF- | (1) |
| Chen et al., [ | (1) 7-day survival rate(2) The escape latency (MWM)(3) Retention Time (MWM)(4) Times across platform (MWM)(5) Swimming speed (MWM)(6) W/D (brain)(7) EB content (brain)(8) The total normal cell count of hippocampus(9) MDA(10) SOD(11) CAT(12) MDA (hippocampus)(13) SOD (hippocampus)(14) CAT (hippocampus)(15) IL-6(16) TNF- | (1) |
| Chen et al., [ | (1) The total normal cell count of hippocampus(2) AI (brain)(3) W/D (brain)(4) Expression of TLR-4 (brain)(5) TNF- | All |
| Gu et al., [ | (1) TNF- | (1) |
| Guo et al., [ | (1) Apoptosis rates of thymocytes(2) VIP (pituitary gland)(3) VIP | All |
| Hu et al., [ | CK-MB |
|
| Hu et al., [ | (1) TNF- | All |
| Hu et al., [ | (1) JMBF(2) DAO (jejunal)(3) XOD (jejunal)(4) MDA (jejunal)(5) W/D (jejunal) | All |
| Hu et al., [ | (1) ALT(2) TNF- | All |
| Hu et al., [ | (1) ALT(2) Cr(3) DAO (liver, renal, and jejunal)(4) W/D (liver)(5) W/D (renal)(6) W/D (jejunal)(7) TNF- | All |
| Huang et al., [ | (1) Survival rate(2) HR(3) MAP(4) NO (lung)(5) NO(6) MPO (lung)(7) W/D (lung)(8) iNOS (lung) (RT-PCR)(9) iNOS (lung) (quantitative real-time PCR)(10) iNOS (lung) (immunoblotting) | (1) |
| Huang et al., [ | (1) BUN(2) Cr(3) AST(4) ALT(5) Total bilirubin(6) HR(7) MAP(8) PMN (renal)(9) MPO (renal)(10) PMN (liver)(11) MPO (liver)(12) NO (renal)(13) NO (liver)14) iNOS mRNA (renal) (15) iNOS mRNA (liver)(16) iNOS protein (renal)(17) iNOS protein (liver) | (1) |
| Yue et al., [ | (1) NLR2 mRNA (lung)(2) RIP2 (lung)(3) TNF- | All |
| Lei et al., △ [ | (1) AI (splenic lymphocyte)(2) Bcl-2 protein (splenic lymphocyte) | All |
| Lei et al., [ | (1) AI (thymocyte)(2) VIP (pituitary gland)(3) VIP | All |
| Lei et al., [ | (1) The escape latency (MWM)(2) Times across platform (MWM)(3) Retention time (MWM)(4) TNF- | All |
| Shi et al., [ | (1) HBF(2) ALT(3) MDA (liver)(4) XOD (liver)(5) W/D (liver) | All |
| Song et al., [ | (1) TNF- | All |
| Song et al., [ | (1) ALT(2) AST(3) HMGB1(4) TNF- | All |
| Villegas-Bastida et al., [ | (1) TNF- | (1) |
| Wang et al., [ | (1) Survival time(2) bp (0 min, 30 min, 60 min, 90 min, 120 min, 150 min, 180 min, 210 min, 240 min, 270 min, 300 min)(3) Temperature (0 min, 60 min, 120 min, 180 min, 240 min, 300 min)(4) HR (0 min, 30 min, 60 min, 90 min, 120 min, 150 min, 180 min, 210 min, 240 min, 270 min, 300 min) | (1) |
| Wang et al., [ | (1) TNF- | All |
| Wang et al., [ | (1) 7d survival rate(2) Lung injury scores(3) Liver injury scores(4) TNF- | All |
| Wu et al., [ | (1) Chiu's scores (intestine)(2) W/D (intestine)(3) TNF- | All |
| Wu et al., [ | (1) HMGB1(2) Ghrelin(3) HMGB1 (intestine)(4) Ghrelin (intestine) | All |
| Wu et al., [ | (1) Ghrelin(2) Ghrelin (intestine)(3) GSH-R (intestine)(4) TNF- | All |
| Xu et al., [ | (1) HR(2) LVEDP(3) LVSP(4) dp/dtmax(5) CO(6) MMP-2 mRNA(cardiac)(7) MMP-9 mRNA (heart)(8) TIMP-1 mRNA (cardiac)(9) TIMP-2 mRNA (cardiac) | All |
| Yang et al., [ | (1) TNF- | (1) |
| Zhang et al., [ | (1) CK-MB(2) TNF- | All |
| Zhang et al., [ | (1) pH (arterial blood)(2) PaO2 (arterial blood)(3) lactate (arterial blood)(4) TNF- | All |
| Zhang et al., [ | (1) CK-MB(2) TNF- | All |
| Zhang et al., [ | (1) Chiu's score (intestine)(2) d-lactate(3) Occludin immunohistochemistry scores(4) Occludin protein expression | All |
| Zhu et al., [ | (1) 36h survival rate(2) intestinal injury score(3) the circulating D-Lactose(4) sIgA content in intestinal mucosa cells(5) CD3+ T lymphocytes(6) | (1) |
Note. ▽A p-value of the comparison between the treatment group and control group at each test time phase unless otherwise stated; △, EA versus S; ◇, EA versus S + SEA;□, CW versus S; ○, PW versus S; ☆, BW versus S; ☼, MA versus S; δ, MA versus S + SEA; φ, pMA versus S; ψ, low-frequency EA versus S; ω, high-frequency EA versus S; EA, electroacupuncture group; MA, manual acupuncture; S, sepsis model group; SEA, sepsis model plus shame EA group; pMA, manual acupuncture pretreatment; CW, continuous waveform; PW, periodic waveform; BW, bipolar waveform; BUN, blood urea nitrogen; Cr, creatinine; MDA, malondialdehyde; SOD, superoxide dismutase; PKCα, protein kinase Ca; HO-1, heme oxygenase-1; Nrf2, NF-E2 related factor 2; AI, apoptosis index; W/D, wet-to-dry ratio; p38MAPK, p38 mitogen-activated protein kinase; α1-M, α1-microglobulin; TNF-α, tumor necrosis factor-α; IL, interleukin; P-Akt, phosphorylated Akt; EB, Evans blue; CO, carbon monoxide; CAT, catalase; GPx, glutathione peroxidase; BALF, bronchoalveolar lavage fluid; ERK, extracellular signal-regulated kinases; CK, creatine kinase; LDH, lactate dehydrogenases; ATP, adenosine triphosphate; ROS, reactive oxygen species; Mfn, mitochondria fusion protein mitofusin; OPA, optic atrophic; Drp, dynamin-related protein; MAP, mean arterial blood pressure; HR, heart rate; LVEDP, left ventricular end diastolic pressure; LVSP, left ventricular end systolic pressure; dp/dt max, left ventricular pressure maximum rising rate; CO, cardiac output; iNOS, inducible nitric oxide synthase; VIP, vasoactive intestinal peptide; NO, nitric oxide; DAO, diamine oxidase; JMBF, the mucosal blood flow of jejunum; XOD, xanthine oxidase; PMN, polymorphonuclear neutrophil; NLR, Nod-like receptor; RIP, receptor interacting protein; HMGB1, high mobility group protein box-1; BCL-2, B-cell lymphoma 2; NF-κB, nuclear factor κB; HBF, hepatic blood flow; NSE, neuron-specific enolase; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase; pH, potential of hydrogen; IFN-γ, interferon-γ; MWM, Morris water maze; Iba, ionized calcium binding adaptor molecule 1.